Literature DB >> 21432277

Treated hypertensives with good medication compliance are still in a state of uncontrolled blood pressure in the Japanese elderly.

Junko Okuno1, Shigeo Tomura, Hisako Yanagi.   

Abstract

OBJECTIVES: Blood pressure (BP) is poorly controlled in many countries. Poor compliance was suggested as the main cause for poor BP control. The purpose of this study was to examine the association between compliance and the control of both casual blood pressure (BP) and 24-hr ambulatory BP in a Japanese elderly population.
METHODS: The study was a cross-sectional survey. Casual BP and 24-hr ambulatory BP were measured at home. Hypertension was defined as casual systolic BP (SBP)≧140 and/or diastolic BP (DBP)≧90 mmHg, or as treated hypertension. A compliance rate of greater than 80% by the pill count method was defined as good compliance.
RESULTS: Of the 178 treated hypertensives, 82.6% showed good compliance. Between the treated hypertensives with good compliance and those with poor compliance, no significant difference was found in either casual BP or ambulatory BP. Of the treated hypertensives with good compliance, the prevalence of achieved target ambulatory BP, i.e., daytime BP<135/85 mmHg, nighttime BP<120/75 mmHg, and 24-hr BP<125/80 mmHg, was, respectively, 35.4%, 43.5%, and 20.4%.
CONCLUSIONS: Casual BP and 24-hr ambulatory BP were poorly controlled in the community-living elderly although many of the treated hypertensives showed good compliance. It is unlikely that this inadequate control of hypertension is due to poor compliance on the part of the subjects.

Entities:  

Keywords:  ambulatory blood pressure monitoring; blood pressure control; community-living elderly; physician’s attitude; poor compliance

Year:  2002        PMID: 21432277      PMCID: PMC2723586          DOI: 10.1007/BF02898004

Source DB:  PubMed          Journal:  Environ Health Prev Med        ISSN: 1342-078X            Impact factor:   3.674


  28 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Compliance and medication knowledge among elderly Japanese home-care recipients.

Authors:  J Okuno; H Yanagi; S Tomura; M Oka; S Hara; C Hirano; S Tsuchiya
Journal:  Eur J Clin Pharmacol       Date:  1999-04       Impact factor: 2.953

3.  Blood-pressure control in the hypertensive population.

Authors:  G Mancia; R Sega; C Milesi; G Cesana; A Zanchetti
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

4.  Inadequate management of blood pressure in a hypertensive population.

Authors:  D R Berlowitz; A S Ash; E C Hickey; R H Friedman; M Glickman; B Kader; M A Moskowitz
Journal:  N Engl J Med       Date:  1998-12-31       Impact factor: 91.245

Review 5.  The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension.

Authors:  L Hansson
Journal:  J Hypertens       Date:  1996-05       Impact factor: 4.844

6.  Current status of antihypertensive therapy for elderly patients in Japan.

Authors:  H Muratani; K Fukiyama; T Kamiyama; Y Kimura; K Abe; M Ishii; J Fujii; I Kuwajima; T Shiomi; Y Kawano; H Mikami; S Ibayashi; T Omae
Journal:  Hypertens Res       Date:  1996-12       Impact factor: 3.872

Review 7.  Actual blood pressure control: are we doing things right?

Authors:  A Coca
Journal:  J Hypertens Suppl       Date:  1998-01

8.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

9.  The prognostic value of ambulatory blood pressures.

Authors:  D Perloff; M Sokolow; R Cowan
Journal:  JAMA       Date:  1983-05-27       Impact factor: 56.272

Review 10.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.